Characterization of a labile naloxone binding site (lambda site) in rat brain

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• A specific high-affinity binding site for naloxone and related 4,5-epoxymorphinans, termed the lambda site, has been identified in rat brain.
• Upon brain tissue homogenization, these lambda sites undergo a rapid conversion from a high-affinity to a low-affinity binding state.

Purpose of the Study:

• To characterize the properties of the lambda binding site, including its affinity changes, temperature dependence, and stereoselectivity.
• To investigate the relationship between lambda site binding and established mu opioid receptors.
• To determine the in vivo binding profile of common opioid drugs at the lambda site.

Main Methods:

• Investigated [3H]naloxone binding kinetics at various temperatures following rat brain homogenization.
• Assessed the effect of proteinase inhibitors, antioxidants, and sulfhydryl agents on lambda site conversion.
• Compared lambda and mu binding kinetics across different temperatures.
• Examined the stability of the low-affinity lambda state and its susceptibility to protease digestion.
• Determined the binding affinity and stereoselectivity of WIN 44,441 isomers at lambda sites.
• Evaluated the influence of sodium chloride and Gpp(NH)p on both high- and low-affinity lambda binding states.
• Assessed in vivo binding of naltrexone, naloxone, nalorphine, and morphine in intact rat brain.

Main Results:

• Lambda sites rapidly transition from high to low affinity at 20°C (t1/2 < 2 min), with slower conversion at lower temperatures.
• Conversion is not prevented by proteinase inhibitors, antioxidants, or sulfhydryl agents.
• Loss of high-affinity lambda binding is temperature-dependent and does not correlate with mu binding changes; partial restoration occurs at 0°C.
• The low-affinity lambda state is protease-sensitive but stable in Tris buffer.
• Binding is stereoselective for the (-)-isomer of WIN 44,441 (KD = 63 nM).
• Lambda site binding is unaffected by NaCl or Gpp(NH)p, unlike mu opioid receptors.
• In vivo, naltrexone, naloxone, nalorphine, and morphine bind to lambda sites in a potency-dependent manner.

Conclusions:

• The lambda site exhibits distinct characteristics from mu opioid receptors, including rapid, temperature-dependent affinity conversion and differential sensitivity to regulatory agents.
• The stereoselective binding and unique pharmacological profile suggest the lambda site represents a novel opioid-related binding entity in the brain.
• These findings have implications for understanding the complex pharmacology of opioid ligands in vivo.